Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

1.1K
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.1K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

1.7K
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
1.7K
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

1.0K
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nurse-led interventions and care for people with bronchiectasis: a pilot study.

British journal of nursing (Mark Allen Publishing)·2026
Same author

Algorithms in Allergy: Diagnosis of Concomitant Inducible Laryngeal Obstruction in Adults With Asthma.

Allergy·2026
Same author

Leucine degradation metabolite ratio as a measure of meropenem susceptibility in carbapenem-resistant <i>Klebsiella pneumoniae</i>.

Microbiology spectrum·2026
Same author

Preventing severe asthma exacerbations in at-risk patients: time for a rethink.

Thorax·2026
Same author

Adverse outcomes in young adults with severe asthma: results from the UK Severe Asthma Registry.

ERJ open research·2026
Same author

Asthma exacerbation profile of benralizumab for severe eosinophilic asthma (the BenRex study): a multicentre, prospective cohort study.

The Lancet. Respiratory medicine·2026
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Related Experiment Video

Updated: Apr 30, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.5K

Inhaled hyperosmolar agents for bronchiectasis.

Anna Hart1, Karnam Sugumar, Stephen J Milan

  • 1Lancaster Medical School, Clinical Research Hub, Lancaster University, Lancaster, Lancashire, UK, LA1 4TB.

The Cochrane Database of Systematic Reviews
|May 13, 2014
PubMed
Summary
This summary is machine-generated.

Inhaled mannitol may increase time to first exacerbation in bronchiectasis patients, with no significant increase in adverse events. Further research is needed for hypertonic saline efficacy in severe disease.

More Related Videos

Bronchoalveolar Lavage BAL for Research; Obtaining Adequate Sample Yield
11:47

Bronchoalveolar Lavage BAL for Research; Obtaining Adequate Sample Yield

Published on: March 24, 2014

75.1K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K

Related Experiment Videos

Last Updated: Apr 30, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.5K
Bronchoalveolar Lavage BAL for Research; Obtaining Adequate Sample Yield
11:47

Bronchoalveolar Lavage BAL for Research; Obtaining Adequate Sample Yield

Published on: March 24, 2014

75.1K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K

Area of Science:

  • Pulmonology
  • Respiratory Medicine
  • Clinical Trials

Background:

  • Mucus retention and bacterial colonization are key features of bronchiectasis, leading to neutrophilic inflammation and airway damage.
  • Hypertonic saline and inhaled dry powder mannitol are investigated for their potential to improve mucus clearance by altering airway surface liquid.
  • These hyperosmolar agents offer a promising, yet under-evaluated, approach to managing mucus stasis in respiratory conditions.

Purpose of the Study:

  • To evaluate the effectiveness of inhaled hyperosmolar substances for treating bronchiectasis.
  • To synthesize evidence from randomized controlled trials on hyperosmolar inhalation therapies in non-cystic fibrosis bronchiectasis.

Main Methods:

  • A systematic literature search was conducted across major databases and trial registries up to April 2014.
  • Randomized controlled trials (RCTs) comparing hyperosmolar inhalation (mannitol or hypertonic saline) with placebo or control in bronchiectasis patients were included.
  • Data extraction and analysis followed standard Cochrane Collaboration methods, with study suitability assessed by two independent reviewers.

Main Results:

  • Eleven RCTs involving 1021 participants were included. Five trials compared inhaled mannitol to placebo.
  • A large trial indicated mannitol increased time to first exacerbation (median 165 vs. 124 days) and reduced antibiotic use for exacerbations, with moderate quality evidence.
  • Evidence suggested mannitol may improve health-related quality of life, with no significant increase in adverse events. Data for hypertonic saline were conflicting and inconclusive.

Conclusions:

  • Inhaled mannitol shows potential to delay exacerbations in bronchiectasis patients, particularly those with near-normal lung function, without increasing adverse events.
  • Further research is recommended for inhaled mannitol in patients with impaired lung function.
  • Robust conclusions on hypertonic saline are not possible due to data limitations; future studies should focus on severe bronchiectasis patients.